Exact Sciences Corporation $EXAS Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC raised its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 25.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 198,287 shares of the medical research company’s stock after acquiring an additional 40,258 shares during the period. Fisher Asset Management LLC owned approximately 0.10% of Exact Sciences worth $10,848,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. William Blair Investment Management LLC grew its position in Exact Sciences by 26.5% during the third quarter. William Blair Investment Management LLC now owns 2,555,051 shares of the medical research company’s stock valued at $139,787,000 after buying an additional 534,881 shares during the period. DNB Asset Management AS boosted its stake in shares of Exact Sciences by 15.5% during the 3rd quarter. DNB Asset Management AS now owns 246,639 shares of the medical research company’s stock worth $13,494,000 after acquiring an additional 33,071 shares in the last quarter. Clearstead Advisors LLC boosted its stake in shares of Exact Sciences by 11.7% during the 3rd quarter. Clearstead Advisors LLC now owns 3,472 shares of the medical research company’s stock worth $190,000 after acquiring an additional 365 shares in the last quarter. Granite Investment Partners LLC acquired a new stake in shares of Exact Sciences during the 3rd quarter valued at about $1,201,000. Finally, Personal CFO Solutions LLC purchased a new position in shares of Exact Sciences in the 3rd quarter valued at about $204,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Stock Up 0.1%

Shares of EXAS opened at $103.50 on Thursday. The company’s 50-day moving average price is $102.58 and its 200 day moving average price is $81.06. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $103.67. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97. The firm has a market cap of $19.76 billion, a P/E ratio of -94.09, a price-to-earnings-growth ratio of 2.35 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. During the same period in the previous year, the business posted ($0.06) earnings per share. The firm’s revenue was up 23.1% compared to the same quarter last year. On average, sell-side analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Barclays reaffirmed an “equal weight” rating and issued a $105.00 price target (up from $77.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Mizuho restated a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research report on Tuesday, January 20th. Robert W. Baird set a $105.00 price target on Exact Sciences in a research report on Thursday, November 20th. Wells Fargo & Company reissued an “equal weight” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Finally, Benchmark lowered Exact Sciences from a “buy” rating to a “hold” rating in a report on Monday, November 24th. Twenty-one analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $92.13.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.